Crossmark Global Holdings Inc. Invests $1.08 Million in Galapagos NV (NASDAQ:GLPG)

Crossmark Global Holdings Inc. purchased a new position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 37,386 shares of the biotechnology company's stock, valued at approximately $1,077,000. Crossmark Global Holdings Inc. owned approximately 0.06% of Galapagos as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Headlands Technologies LLC increased its position in shares of Galapagos by 56.7% during the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 446 shares during the last quarter. GAMMA Investing LLC raised its position in Galapagos by 140.7% during the third quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 736 shares in the last quarter. Rhumbline Advisers lifted its stake in Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company's stock valued at $113,000 after acquiring an additional 814 shares during the last quarter. Signaturefd LLC grew its position in shares of Galapagos by 48.1% in the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 1,258 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Galapagos by 63.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 1,510 shares during the last quarter. Institutional investors own 32.46% of the company's stock.

Galapagos Trading Down 3.4 %

Shares of GLPG traded down $0.94 during midday trading on Friday, hitting $26.96. The company's stock had a trading volume of 238,114 shares, compared to its average volume of 143,660. Galapagos NV has a one year low of $24.16 and a one year high of $42.46. The company's fifty day simple moving average is $28.92 and its two-hundred day simple moving average is $27.62.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Leerink Partners assumed coverage on Galapagos in a report on Monday, September 9th. They set a "market perform" rating and a $24.00 target price on the stock. Royal Bank of Canada dropped their price objective on shares of Galapagos from $32.00 to $30.00 and set a "sector perform" rating on the stock in a research report on Friday, November 1st. Raymond James downgraded shares of Galapagos from an "outperform" rating to a "market perform" rating in a report on Friday, August 2nd. Finally, Leerink Partnrs raised shares of Galapagos to a "hold" rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company's stock. According to data from MarketBeat.com, Galapagos has a consensus rating of "Hold" and a consensus price target of $30.75.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.